EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Avidity maturation of anti‐spike IgG after vaccination in COVID ‐19 convalescent vs COVID ‐19 naïve patients

Emma Löfström iD, Anna Eringfält, Arne Kötz, Johan Tham, Johan Undén

APMIS · 2025

DOI: 10.1111/apm.13489 ↗

Kurz gefasst

Fachartikel in der Zeitschrift APMIS, 2025. Verfasst von Emma Löfström und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Lund University, Office DCSL, Lund, Sweden. Hauptthemen laut MEDLINE: Immunoglobulin G, COVID-19, Antibody Affinity, Antibodies, Viral. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Södra sjuvårdsregionen (Southern medical care region, Sweden), Region Halland, Sparbanksstiftelsen Varberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies and avidity maturation contribute to long‐lasting immunity, and previous COVID‐19 seems to enhance the immune response after vaccination. The aim of this study was to compare the immune response after vaccination between COVID‐19 convalescents and naïve patients. Blood samples from COVID‐19 convalescents and naïve patients, taken 1, 3 and 6 months after the second dose of vaccine (mRNA‐vaccine BNT162b2), were analysed for anti‐spike IgG and avidity. Questionnaires concerning side effects were used. Thirty‐one patients in the COVID‐19 cohort and 30 patients in the naïve cohort were included. High levels of anti‐spike IgG and avidity index were seen. Anti‐spike IgG were significantly higher in the COVID‐19 cohort and declining (median 1250, 566, 282 RU/ml vs 565, 187, 65 RU/ml). Avidity did not change over time (median at 6 months 78% vs 65%). The most common side effects were pain at the injection site, malaise and headache. In conclusion, high levels of anti‐spike IgG after vaccination were seen and most patients developed high‐avidity antibodies, although antibody levels and avidity were higher in the COVID‐19 cohort. Over time, the levels of anti‐spike IgG declined, yet avidity remained high. Side effects did not differ between groups and were of short duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin GCOVID-19Antibody AffinityAntibodies, ViralSARS-CoV-2Spike Glycoprotein, CoronavirusBNT162 VaccineVaccinationHumansMaleFemaleMiddle AgedAdultAgedCOVID-19 VaccinesCohort Studies

Stichwörter der Autor:innen

Avidity indexCOVID‐19anti‐spike IgGimmune responsevaccination

Substanzen

Immunoglobulin GAntibodies, ViralSpike Glycoprotein, CoronavirusBNT162 Vaccinespike protein, SARS-CoV-2COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Clinical Sciences, Lund University, Office DCSL, Lund, Sweden.
  • Department of Clinical Microbiology, Hallands hospital Halmstad, Halmstad, Sweden.
  • Department of Translational Medicine, Clinical Infection Medicine, Lund University, Skåne University Hospital, Malmö, Sweden.
  • Department of Operation and Intensive care, Hallands hospital Halmstad, Halmstad, Sweden.

ORCID-Profile: Emma Löfström

Förderung

  • Södra sjuvårdsregionen (Southern medical care region, Sweden)
  • Region Halland
  • Sparbanksstiftelsen Varberg

Zitieren

APA

Löfström, E., Eringfält, A., Kötz, A., Tham, J., & Undén, J. (2025). Avidity maturation of anti‐spike IgG after vaccination in COVID ‐19 convalescent vs COVID ‐19 naïve patients. APMIS. https://doi.org/10.1111/apm.13489

Vancouver

Löfström E, Eringfält A, Kötz A, Tham J, Undén J. Avidity maturation of anti‐spike IgG after vaccination in COVID ‐19 convalescent vs COVID ‐19 naïve patients. APMIS. 2025. doi:10.1111/apm.13489

BibTeX
@article{Lfstrm2025,
  author = {Löfström, Emma and Eringfält, Anna and Kötz, Arne and Tham, Johan and Undén, Johan},
  title = {Avidity maturation of anti‐spike IgG after vaccination in COVID ‐19 convalescent vs COVID ‐19 naïve patients},
  journal = {APMIS},
  year = {2025},
  doi = {10.1111/apm.13489}
}
Kostenlos starten →